DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTICONVULSANT EVALUATION OF 6-METHYL-2-ARYLAMINOPYRIMIDIN-4(3H)-ONE

H. Severina, N. Voloshchuk, N. Saidov, V. Georgiyants

1. Introduction

To date, epilepsy remains one of the most common neurological diseases [1]. It has a chronic course and in the case of irrational treatment leads to mental, severe cognitive and behavioral disorders, personality disorders, etc. [2]. Studies have consistently demonstrated comorbid associations of epilepsy with numerous psychiatric and somatic conditions [3]. These include not only structural and functional CNS disorders such as stroke, dementia and migraines, but also heart disease, hypertension, chronic obstructive pulmonary disease, etc.

Despite the slight progress in understanding some aspects of the pathophysiology of epileptogenesis [4, 5], the development of a number of new anti-epileptic drugs (AEDs) and established mechanisms of anticonvulsant action [6, 7], the spread of refractory forms of epilepsy [8, 7] and the development of a wide range of side effects in the treatment of existing AEDs [9] remains a major problem today. That is why design of new AEDs with a maximum security profile remains a pressing issue. Priority methods for implementing modern “drug-design” are structural variations of known AEDs and selective target-oriented screening [10]. One such drug is phenobarbital (Fig. 1), which is still used for the treatment of convulsive status epilepticus in infants and children [11] and is the drug of choice for refractory forms of epilepsy [12]. The introduction of a hydrophobic methyl group into the structure of phenobarbital resulted in methylphenobarbital (mephenobarbital), a drug with distinct anticonvulsant properties, which is effective in resistant forms of epilepsy due to the fact that it is not a substrate for P-glycoprotein [13].

Copyright © 2020, H. Severina, N. Voloshchuk, N. Saidov, V. Georgiyants. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0).
Another structural analogue of phenobarbital is 1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid (T2000) [14]. The drug has undergone the first phase of clinical trials as a treatment for epilepsy and essential tremor in Parkinson's disease. In addition, our studies have identified a number of substances with significant anticonvulsant properties among pyrimidine-4(3H)-one derivatives [15] and its annelated derivatives [16].

The aim of this study was to synthesize 2-aminoaryl derivatives of 6-methyl-pyrimidin-4(3H)-one, a virtual target-oriented screening followed by a study of anticonvulsant activity in the rat pentylene-tetrazole seizures model and to discuss “structure-activity” patterns.

2. Planning (methodology) of research
The presented study is based on the modification of the "pyrimidine" matrix - the main pharmacophore fragment of phenobarbital and includes all stages of the concept of modern "drug-design".

1. Design of target molecules on the basis of logical and structural analysis of the literature data on the "structure-activity" interaction and the basic principles of the pharmacophore concept.

The positive effect of acetamide and phenyl fragments on anticonvulsant activity has been previously evaluated (Fig. 2) [15, 17]. Continuing research on the establishment of pharmacophore anticonvulsant fragments into the structure of 6-methyl-pyrimidin-4(3H)-one, a 2-aminoaryl moiety is introduced.

Comparison with the preliminary results of 2-thioacetanilide derivatives will allow to evaluate the role of thioacetate and aminophenyl moiety in the manifestation of anticonvulsant activity. In addition, such modification is quite promising in terms of the ability to interact with the active site of the receptor, since the target substances remain lipophilic domains in the form of an aryl ring and methyl group, a hydrogen bond domain to further stabilize the ligand-receptor conformation, as well as the donor electrons to form covalent bonds.

2. Synthesis and structure determination of new 2-aminoaryl derivatives of 6-methyl-pyrimidin-4(3H)-one.
3. Virtual target-oriented screening of investigated ligands using flexible molecular docking tools. Evaluation of the affinity of the ligands to the active sites of GABA_A and GABA_Aγ will allow us to select the most promising compounds for investigation on the PTZ seizures model.
4. Pharmacological screening on a PTZ seizures model in rats.
5. SAR analysis of the results.

3. Materials and methods
All solvents and reagents were obtained from commercial sources. The melting points (°C) were determined in a capillary using an electrothermal IA9100X1 (Bibby Scientific Limited, Staffordshire, UK) digital melting point apparatus. 1H NMR spectra were recorded on a Bruker Varian Mercury instrument (Varian Inc., Palo Alto, CA, USA) (400 MHz) in DMSO-d6 internal TMS standard. Chromatography-mass spectrometric analysis was performed on a PE SCIEX API
150EX chromatograph. Elemental analysis was performed on a Euro Vector EA-3000 microanalyzer (Eurovector SPA, Redavalle, Italy). The content of the elements was within ± 0.4 % of theoretical values.

6-Methyl-2-thiopyrimidin-4(3H)-one (1) was obtained earlier [15].

**Synthesis of 6-methyl-2-methylthiopyrimidin-4(3H)-one (2).**

A. A mixture of 6-methyl-2-thiopyrimidin-4 (3H) -one (3) (1.42 g, 10 mmol), dimethyl sulfate (1.94 ml, 10 mmol), potassium carbonate (2.76 g, 20 mmol), ethanol (50 ml) is stirred for two hours at room temperature. The reaction time was determined by thin layer chromatography, the solvent system chloroform-butanol (9: 1), the developer - iodine vapour. After the reaction, the ethanol was evaporated in vacuum. The residue was dispersed to cold water (50 ml) acidified with hydrochloric acid. The precipitate is filtered off and dried. Further reactions can be used without further purification. If necessary, recrystallized from ethanol. The melting point 217–220 °C corresponds to the literature [18]. Yield 94 %.

B. To a freshly prepared solution of sodium methy late (0.62 g, 27 mmol sodium / 100 ml anhydrous methanol) was added 6-methyl-2-thiopyrimidin-4(3H)-one (1) (3.50 g, 24.6 mmol) and heated the reaction mixture to 40 °C, then methyl iodide (6.53 ml, 24.6 mmol) was added. The mixture was refluxed for 3 hours, naturally cooled and left for 12 hours. The precipitate was washed with methanol and dried. The yield was 92 %, melting point 217–220 °C corresponds to the literature.

**General method of synthesis of 6-methyl-2-arylamino.pyrimidin-4(3H)-one (3.1-3.9).**

A mixture of 0.01 mol (1.56 g) of 6-methyl-2-methylthiopyrimidin-4(3H)-one (2) and 0.01 of the corresponding arylamine was heated to 140 °C until methanethiol had ceased to secrete. The resulting residue is gradually triturated with ethanol and the formed precipitate is filtered off. Wash twice with 20 ml ethanol, dry and crystallize from dimethylformamide. Compound 3.1 has been described in the literature [19].

**Molecular docking**

Flexible molecular docking was performed using AutoDock Vina. The ability of the docking algorithm used to reproduce the experimental data was evaluated by reference to the native ligand annealing. As biological targets were used macromolecules from Protein Data Bank (PDB) [20]: GABA\_R (PDB ID – 4COF), GABA\_A\_1 (PDB ID – 10IW).

**Preparation of ligands**

Structures 3.1-3.9 were obtained using MarvinSketch 18.23 and saved in mol format. Optimized by Chem3D using molecular-mechanical MM2 algorithm and saved as pdb files. Using AutoDockTools-1.5.6, the pdb files have been converted to PDBQT [21].

**Preparation of proteins**

PDB files are downloaded from the PDV protein database. Discovery Studio Visualizer 2017 / R2 was used to remove water and ligand molecules from the crystal. Protein structures were saved as pdb files. In AutoDockTools-1.5.6, polar hydrogen is added to the protein structure and stored as PDBQT. Grid boxes were installed on native ligands. AutoDock Vina was used for docking [21]. Discovery Studio V17.2.0.16349 was visualized and analysed for the obtained docking results.

**Anticonvulsant activity.**

**Animals**

Anticonvulsant activity was studied in adult Wistar rats of two genders (150-170 g) obtained from the vivarium of the "Institute of Pharmacology and Toxicology of AMS of Ukraine". The animals were kept at the vivarium of National Pirogov Memorial Medical University, Vinnytsya. All animals were acclimatized for a period of ten days before the start of the experiments. During the experiments, the animals were in vivarium at t = 19–24 °C, humidity not more than 60 %, natural "day/night" light mode in polypropylene cages on a standard diet with free access to water and food [22]. The studies were conducted in accordance with the principles of Directive 210/63 / EU of the European Parliament and the Council of the EU "On the protection of animals used for scientific purposes" (Brussels, 2010) and "General ethical principles for animal experimentation" (Kyiv, 2001), Law of Ukraine “On the Protection of Animals from Cruelty” No. 3477-IV of February 21, 2006, as amended, and the Order of the Ministry of Youth and Sports of Ukraine “On Approval of the Procedure for Scientific Experiments with Animals in Scientific Institutions” No. 249 of March 1, 2012.

**Pentylenetetrazole seizures**

Screening studies of potential anticonvulsants were performed within the international outsourcing program – Antiepileptic Drug Development Program [23]. The test compounds were administered at a dose of 80 mg/kg intramuscularly for 30 min before the introduction of pentylenetetrazole. The convulsive condition in animals was simulated by single subcutaneous administration of pentylenetetrazole ("Sigma", USA) at a dose of 80 mg/kg. After introduction of the convulant, each animal was placed in a separate plastic cylindrical box with a diameter of 20 cm and a height of 35 cm. The animals were continuously monitored for 60 minutes. The manifestation of anticonvulsant action was evaluated by the dynamics of the latent, the nature and duration of the seizure in minutes, as well as the mortality rate. The severity of seizures was determined in points [24].

**Statistical analysis**

All values were expressed as the means ± S.E.M. The data was analysed by ANOVA (analysis of variance) followed by Dunnett’s test (Statistical package for social sciences, SPSS 16.0, USA). An X2 analysis was performed to compare the neurotoxicity differences (number of failures per test). P values ≤ 0.05 was considered as significant.

**4. Result**

The original 6-methyl-2-thiopyrimidin-4(3H)-one (1) was previously obtained by condensation of thiourea and acetoacetic ester in the medium of ethyl alcohol, respectively, in the presence of sodium hydroxide (Fig. 3) [15, 25].
Methylation of 6-methyl-2-thiopyrimidin-4(3H)-one (1) was performed in two ways: using dimethyl sulfate (A) and methyl iodide (B), medium K₂CO₃ / EtOH and MeONa / MeOH, respectively. The yields of the reaction products were high in both cases, allowing the use of both reagents for alkylation of the thio group. By heating the resulting 6-methyl-2-methylthio-pyrimidin-4(3H)-one (2) with aromatic amines at 140 °C, the target 2-arylaminopyrimidines (3.1–3.9) were obtained. The choice of substituents in the phenyl radical was based on their own research findings on their effect on anticonvulsant activity [15, 17].

Synthesized compounds (3.1–3.9) are white crystalline substances with clear melting points, insoluble in water, readily soluble in dioxane and dimethylformamide. The structure of the synthesized compounds was proved by the method of 1H NMR spectroscopy, molecular masses and individuality – chromatomass spectrometry, composition – elemental analysis (Tables 1, 2).

**Table 1**

| № n/n | R         | Yield % | MP °C | Gross formula | MM   | Calculated, % | Found, % | LC/MS m/z, % |
|--------|-----------|---------|-------|---------------|------|---------------|----------|--------------|
| 3.1*   | H         | 80      | 255-7 | C₁₁H₁₁N₃O    | 201.22 | 65.71, 65.43  | 5.51, 5.2 | 20.90, 20.82 | 202.09 (96) |
| 3.2    | 4-Me      | 78      | 225-7 | C₁₂H₁₃N₃O    | 215.26 | 66.96, 66.78  | 6.09, 6.07 | 19.52, 19.59 | 216.1 (96)  |
| 3.3    | 4-Et      | 77      | 207-9 | C₁₃H₁₅N₃O    | 229.12 | 68.10, 67.97  | 6.59, 6.56 | 18.33, 18.37 | 230.1 (97)  |
| 3.4    | 4-Br      | 81      | 248-50| C₁₁H₁₀BrN₃O | 280.13 | 47.17, 47.01  | 3.60, 3.58 | 15.00, 15.04 | 281.0 (96)  |
| 3.5    | 3-CF₃     | 66      | 240-2 | C₁₂H₁₀F₃N₃O | 269.23 | 53.54, 53.47  | 3.74, 3.72 | 15.61, 15.60 | 270.0 (95)  |
| 3.6    | 3-OMe     | 81      | 194-6 | C₁₂H₁₃N₃O₂   | 231.26 | 62.33, 62.27  | 5.67, 5.65 | 18.17, 18.20 | 232.1 (96)  |
| 3.7    | 4-OMe     | 85      | 220-2 | C₁₂H₁₃N₃O₂   | 231.26 | 62.33, 62.30  | 5.67, 5.66 | 18.17, 18.18 | -            |
| 3.8    | 3,4-diCl  | 84      | 255-7 | C₁₁H₈Cl₂N₃O | 270.11 | 48.91, 48.82  | 3.36, 3.35 | 15.56, 15.58 | 271.2 (97)  |
| 3.9    | 2,3-Me    | 77      | 234-6 | C₁₁H₁₃N₃O   | 229.28 | 68.10, 67.96  | 6.59, 6.57 | 18.33, 18.37 | -            |

*Melting point and the IR spectrum of compound 3.1 as described in the literature [Abdel-Samei]

The character of the 1H NMR spectra of the synthesized compounds (3.1–3.9) fully corresponds to their structure: the singlet signal of the region 11.35–10.35 ppm is characteristic of the NH = O proton in the third position of the pyrimidine cycle (lactam form); the proton of the NH group is fixed at the site of 8.95–8.22 ppm; the singlet signal of the methin proton at the 5 position of the pyrimidine cycle resonates in the region of 5.80–5.52 ppm; three protons of the methyl radical resonate as a singlet about 2.20–2.10 ppm; the character of the aromatic proton signals is characteristic of the location of the substituents in the phenyl ring.
Table 2

| Compound | NHCO, c/1H | NH, c/1H | Ar-H | CH₅, c/1H | CH₃c/2H | Signals of other protons |
|----------|------------|----------|------|----------|---------|------------------------|
| 3.1      | 10.51      | 8.95     | 7.66, 2H, d, J=8.1, H-2',6' | 5.71     | 2.13    | –                      |
| 3.2      | 10.52      | 8.81     | 7.43, 2H, d, J=8.2, H-3',5' | 5.68     | 2.13    | 2.23. 1H, c, CH₃       |
| 3.3      | 10.35      | 8.39     | 7.47 2H, d, J=8.4, H-3',5' | 5.52     | 2.14    | 2.62 q, 2H, CH₃        |
| 3.4      | 10.52      | 8.82     | 7.63 2H, d, J=8, H-3',5'   | 5.72     | 2.15    | –                      |
| 3.5      | 11.24      | 8.94     | 7.62-7.50 m, 2H, H-2',4'   | 5.80     | 2.20    | –                      |
| 3.6      | 10.50      | 8.82     | 7.42 1H, s, H-2'           | 5.72     | 2.12    | 3.75 3H, s, OCH₃       |
| 3.7      | 10.25      | 8.22     | 7.48 2H, d, J=8, H-3',5'   | 5.55     | 2.12    | 3.75 3H, s, OCH₃       |
| 3.8      | 10.60      | 8.88     | 8.02 1H, s, H-2'           | 5.65     | 2.20    | –                      |
| 3.9      | 10.52      | 8.81     | 7.52 1H, d, J=8, H-4'     | 5.55     | 2.10    | 2.30, 3H, s, CH₃       |

The appropriateness of the anticonvulsant activity study was further evaluated using molecular docking tools in biotargeting. The synthesized compounds are structural analogues of substances that exhibit activity on the pentylenetetrazole seizures model. Mechanism of convulsive action of PTZ is caused by blocking of chloride ionophore of GABAₐ-benzodiazepine complex [10]. The effect of arylamines (3.1-3.9) on the GABA-ergic system is predicted by their affinity for the allosteric site of the GABAₐ receptor (PDB 4COF) [26] and the GABA aminotransferase enzyme GABA AT (PDB-10HW) [27]. The ability of the docking algorithm to reproduce the experimental data was confirmed by the estimation of the affinity and conformation of the native ligands of benzamidine (BA), a new GABAₐR agonist, and vigabatrin (VGN) with active GABAₐR and GABAAT sites, respectively (Figs. 4–6). Another reference ligand was phenobarbital (PHB) as an analogue in structure with GABAergic mechanism of action. Binding energy (scoring function) became a quantitative characteristic (Table 3). 3D visualization of the reference and the studied conformations on the example of 4-methylphenyl derivative (4.2) is presented in Fig. 4, 5: hydrogen bonds are indicated by green dotted lines, hydrophobic interactions – purple dotted lines.

Table 3

| Targets | Ligands | PHB | VGN | BA |
|---------|---------|-----|-----|----|
| GABAₐR  | –6.5    | –8.0| –6.5| –6.8|
|         | –6.8    | –5.4| –5.9| –7.1|
|         | –5.4    | –7.0| –7.0| –6.7|
|         | –7.2    | –6.8| –6.7| –8.5|
|         | –8.4    | –    | –    | –    |

The binding energies of all the synthesized ligands, although illustrating the affinity for GABA biomass, are higher than the binding energies of the comparison drugs (Table 3). The best scoring function with both targets was calculated for the 4-methoxy substituted derivative (3.7): -7.2 against 8.5 kcal / mol in benzamidine in the case of GABAₐR and -7.2 against -8.4 kcal / mol in vigabatrin when docked in GABAₐ. The lowest binding energies are predicted for the CF3 substituted derivative (3.5). A detailed comparative analysis of the conformations of the ligands (3.1-3.9) in the active site GABAₐR showed that immersion in the pocket occurs aryl fragment (Fig. 4d), which reacts hydrophobically with tyrosine residues (Tyr62A, 205B) and phenylalanine (Phe200B). These residues in the experiment interact with the native ligand (Fig. 4).
The pyrimidine moiety remains in the input portion of the hydrophobic pocket, and the protein moieties asparagine (Asp43A), isoleucine (Ile42), alanine (Ala201) are not positioned in the experiment as amino acids of the active site. At the simultaneous placement in the active site of BA, PHB and the investigated ligands (3.1-3.9) (Fig. 5a) it is evident that the pyrimidine moiety (yellow molecule) is only partially immersed in the active site and does not overlap even with the pyrimidine cycle of phenobarbital, which also occupies a slightly “shallower” position compared to benzamidine.

In a detailed analysis of the position of the ligands (3.1-3.9) in the active site of GABA-AT, it should be noted that only two amino acid residues interacting with the vigabatrin – valin (Val300) and phenylalanine (Phe189) – are involved in the hydrophobic interaction. Other interactions occur with amino acids, which in the experiment capture the cofactor GABA-AT – pyridoxal-5-phosphate (PLP) – threonine (Thr353) and cysteine (Cys135). At the simultaneous placement in the active site of VGN, PLP and the investigated ligands (3.1-3.9) (Fig. 4b), it is evident that the pyrimidine cycle is immersed in the hydrophobic pocket much deeper than the vigabatrin and overlaps with the pyrimidine cycle of PLP. This conformational arrangement in the active sites cannot be considered optimal, but does not exclude the possible agonistic effect on GABA<sub>A</sub> and inhibitor one on GABA-AT.
Thus, given the ambiguous molecular docking rates for screening for anticonvulsant activity on the PTZ model, we selected only 4 compounds out of 9, which showed relatively better docking results with both biotargets. In addition, compound 2 was explored to better understand the effect of substituents on activity.

All of the studied phenylamines (3) did not show a significant anticonvulsant effect: seizures occurred on the background of PTZ and tested compounds administration, and significant mortality was observed (Table 1). In all animals of the control group, PTZ administration induced a convulsive condition (Table 4), which was accompanied by pronounced tonic-clinical convulsions and 100% mortality. Phenobarbital significantly prevented the lethality and development of convulsive syndrome, while lamotrigine partially protected the animals from the chemotoxic effect of pentylenetetrazole, leaving convulsive twitching, jumps and tonic contractions of the forelimbs. Lamotrigine significantly prolonged the latency period 5.8 times, decreased the severity and duration of seizures relative to control, and the mortality rate was 20% of animals.

According to the screening results, only 4-methoxyphenylamine (3.7) according to the criterion of the integral protective indicator - a decrease in mortality compared to control statistically significantly prevented mortality in 100% of animals. However, it was inferior to the comparison drugs in all indicators of the convulsive syndrome (Table 4). 4-bromophenylamine (3.4) also reduced the mortality rate by up to 20% and extended the latency period twice, reduced the intensity and severity of seizures.

Table 4

| Groups of animals | Number of rats | Dose mg/kg | Duration of the latent period, min | Duration of seizures, min | Lethality abs. units (%) | Intensity of seizures, (points) |
|-------------------|----------------|------------|-----------------------------------|---------------------------|--------------------------|--------------------------------|
| Control           | 10             | ~          | 4.7±0.30                          | 9.70±0.90                 | 10 (100%)                | 4.96                           |
| 2                 | 5              | 80         | 9.0±1.5*                          | 18.6±3.7*                 | 5 (100%)                 | 4.9                            |
| 3.1               | 5              | 80         | 8.8±1.1*                          | 12.6±2.9                  | 3 (60%)                  | 4.4                            |
| 3.4               | 5              | 80         | 10.2±3.6*                         | 4.4±1.3*                  | 1 (20%)                  | 2.0                            |
| 3.7               | 5              | 80         | 12.8±1.7*                         | 8.2±1.2*                  | 0*                       | 2.4                            |
| 3.8               | 5              | 80         | 6.0±0.7                           | 7.0±1.0*                  | 5 (100%)                 | 4.6                            |
| PNB               | 5              | 20         | 30.0±0.0*                         | 0*                        | 0*                       | 0                              |
| Lamotrigine       | 5              | 20         | 27.6±0.8*                         | 2.40±0.40*                | 1 (20%)                  | 2.20                           |

Footnotes: * – compared to control group indicators p<0.05

5. Discussion

The complete reproduction of the conditions of the previous pharmacological experiment allows us to compare the results and discuss some regularities of the influence of molecule fragments on anticonvulsant activity. As with the acetanilide derivatives of thiopyrimidine-4(3H)-one [15], among phenylamines (3), the best performance also showed 4-Br and 4-OMe substituted derivatives, however, they have significantly lower rates of protection against PTZ seizure, which in turn allows us to predict the positive effect of thioacetamide. Once again, the positive effect of the phenyl moiety itself became apparent, as compound 2 proved to be completely indifferent to PTZ seizure protection. The lack of seizure protection and 100% lethality of animals using 2,4-dichlorophenylamine (3.8) is completely correlated with the results regarding the negative effect of chlorine atoms in the phenyl radical and the increase in mortality of the experimental animals in the presence of chlorine atoms in the phenyl radical [15, 17].

A positive correlation was found between in vivo studies on PTZ seizure model and scoring functions and conformational placement of ligands in the active
GABA$_A$ site and the GABA$_A$T enzyme, which substantiates the feasibility of target-based virtual screening to streamline pharmacological screening.

6. Conclusions

6-methyl-2-arylaminopyrimidin-4 (3H)-one was synthesized as structural analogues of phenobarbital and promising anticonvulsants. According to the results of the docking of the investigated ligands into active sites of GABA$_A$ receptor and GABA$_A$T in comparison with benzamidine, phenobarbital and vigabatrin compounds for pharmacological screening were selected. Only 2 compounds tended to have an anticonvulsant effect on the PTZ seizures model in rats, preventing mortality in 100% of cases and prolonging the latency period. The established relationship between the conformational placement of ligands in active GABA$_A$ receptor sites and GABA$_A$T and screening data allows us to recommend the presented docking methodology as a tool for streamlining screening on the PTZ seizures model. The positive role of thioacetamide and phenyl fragments, as well as 4-Br, 4-MeO radicals in the manifestation of anticonvulsant activity, was proved.

Study Limitations. Using a different docking methodology or other computer programs for docking data of scoring functions may be different.

Prospects for further research. According to current approaches to the search for new antiepileptic drugs [28] despite the lack of significant results on the PTZ seizures model for this group of compounds screening for the maximum electroshock (MES) model and the psychomotor (6 Hz) model of seizures in mice is recommended as this techniques characterize different mechanisms of anticonvulsant action.

Conflict of interests

There are no conflicts of interest regarding this study.

References

1. Gesche, J., Christensen, J., Hjalgrim, H., Rubboli, G., Beier, C. P. (2020). Epidemiology and outcome of idiopathic generalized epilepsy in adults. European Journal of Neurology, 27 (4), 676–684. doi: http://doi.org/10.1111/ene.14142
2. Yuen, A. W. C., Keezer, M. R., Sander, J. W. (2018). Epilepsy is a neurological and a systemic disorder. Epilepsy & Behavior, 78, 57–61. doi: http://doi.org/10.1016/j.yebeh.2017.10.010
3. Keezer, M. R., Sisodiya, S. M., Sander, J. W. (2016). Comorbidities of epilepsy: current concepts and future perspectives. The Lancet Neurology, 2 (15), 106–15. doi: http://doi.org/10.1016/s1474-4422(15)00225-2
4. Kubova, H., Lukasiuk, K., Pitkanen, A. (2012). New insights on the mechanisms of epileptogenesis in the developing brain. Pediatric Epilepsy Surgery. Vienna: Springer, 3–44. doi: http://doi.org/10.1007/978-3-7091-1360-8_1
5. Pitkanen, A., Lukasiuk, K., Dukek, F. E., Staley, K. J. (2015). Epileptogenesis. Cold Spring Harbor perspectives in medicine, 5 (10). doi: http://doi.org/10.1101/cshperspect.a022822
6. Vossler, D. G., Weingarten, M., Gidal, B. E. (2018) Summary of antiepileptic drugs available in the United States of America working toward a world without epilepsy. Epilepsy currents, 18 (4), 1–26. doi: http://doi.org/10.1016/j.epchl.2017.12.006
7. Bieler, M., Cross, H., Hedrich, U. B. S., Lagacé, L., Lerche, H., Loddenkemper, T. (2019). Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy & Behavior, 101, 106564. doi: http://doi.org/10.1016/j.yebeh.2019.106564
8. Golayla, A., Kwan, P. (2017). Drug development for refractory epilepsy: The past 25 years and beyond. Seizure, 44, 147–156. doi: http://doi.org/10.1016/j.seizure.2016.11.022
9. Gaitatzis, A., Sander, J. W. (2013). The Long-Term Safety of Antiepileptic Drugs. CNS Drugs, 27 (6), 435–455. doi: http://doi.org/10.1007/s40263-013-0063-0
10. Bieler, M., White, H. S. (2010). Key factors in the discovery and development of new antiepileptic drugs. Nature Reviews Drug Discovery, 9 (1), 68–82. doi: http://doi.org/10.1038/nrd2997
11. Hubert, P., Parain, D., Vailleé, L. (2009). Management of convulsive status epilepticus in infants and children. Revue neurologique, 165 (4), 390–397. doi: http://doi.org/10.1016/j.neuro.2008.11.009
12. Zhang, Q., Yu, Y., Lu, Y., Yue, H. (2019). Systematic review and meta-analysis of propofol versus barbiturates for controlling refractory status epilepticus. BMC Neurology, 19, 1–22. doi: http://doi.org/10.1186/s12883-019-1281-y
13. Mairinger, S., Bankstahl, J. P., Kuntner, C., Römermann, K., Bankstahl, M., Wanek, T. et al. (2012). The antiepileptic drug mephobarbital is not transported by P-glycoprotein or multidrug resistance protein 1 at the blood–brain barrier: A positron emission tomography study. Epilepsy Research, 100 (1–2), 93–103. doi: http://doi.org/10.1016/j.eplepsyres.2012.01.012
14. Tahar, A. H., Chiang, R., Steeves, T., Jog, M., Lang, A., Grimes, D. (2013). Efficacy and safety of T2000 in older patients with essential tremor. Parkinsonism & Related Disorders, 19 (4), 485–486. doi: http://doi.org/10.1016/j.parkreldis.2012.11.014
15. Severina, H., Skupa, O., Khairulin, A., Voloschuk, N., Georgiyants, V. (2019). Synthesis and anticonvulsant activity of 6-methyl-2-thioxo-2,3-dihydrodipyrimidin-4(1H)-one acetamides. Journal of Applied Pharmaceutical Science, 9 (2), 12–19. doi: http://doi.org/10.7324/japs.2019.90202
16. El Kayal, W. M., Shtrygol, S. Y., Zalevskiy, S. V., Shark, A. A., Tsyvunin, V. V., Kovalenko, S. M. et al. (2019). Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)acetamide. European journal of medicinal chemistry, 180, 134–142. doi: http://doi.org/10.1016/j.ejmech.2019.06.085
17. Severina, H., Skupa, O. O., Voloschuk, N. I., Suleiman, M. M., Georgiyants, V. A. (2019). Synthesis and anticonvulsant activity of 6-methyl-2-(2-oxo-2-arylethyl)thio)pyrimidin-4(3 H)-one derivatives and products of their cyclization. Pharmacia, 66 (3), 141–146. doi: http://doi.org/10.3897/pharmacia.66.e38137
18. Kotaiah, S., Ramadevi, B., Naidu, A., Dubey, P. K. (2013). A Green and Facile Synthesis of 6-Methyl-2-(alkylthio)pyrimidin-4(3H)-one. Asian Journal of Chemistry, 25 (17), 9869–9871. doi: http://doi.org/10.14233/ajchem.2013.15532
19. Abdel-Fattai, A. S. M., Negm, A. M., Gafar, F. E. M. (1992). Reactions with 6-methyl-2-thiouracil synthesis of dipyrimidino[2,1-B:1′,2′-C]thiazine. A new ring system. Phosphorus, Sulfur, and Silicon and the Related Elements, 72 (1–4), 145–156. doi: http://doi.org/10.1080/10426509208031548
20. Protein Data Bank. Available at: http://www.rcsb.org/pdb/home/home.do
21. Trotz, O., Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multitargeting. Journal of computational chemistry, 31 (2), 455–461. doi: http://doi.org/10.1002/jcc.21334
22. Deacon, R. M. J. (2006). Housing, husbandry and handling of rodents for behavioral experiments. Nature Protocols, 1 (2), 936–946. doi: http://doi.org/10.1038/nprot.2006.120
23. Stables, J. P., Kupferberg, H. J.; Avanzini, G., Tanganelli, P., Avoli, M. (Eds.) (1997). The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project. Molecular and cellular targets for antiepileptic drugs. London: John Libbey & Company Ltd, 4–17.
24. Gerald, M. C., Riffee, W. H. (1973). Acute and chronic effects of d- and 1-amphetamine on seizure susceptibility in mice. European Journal of Pharmacology, 21 (3), 323–330. doi: http://doi.org/10.1016/0014-2999(73)90134-9
25. Barmaki, M., Valiyeva, G., Maharramov, A. A., Allaverdiyev, M. M. (2013). Synthesis of 2,3-Dihydro-6-methyl-2-thiopyrimidin-4(1H)-one (6-Methylthiouracil) Derivatives and Their Reactions. Journal of Chemistry, 2013, 1–6. doi: http://doi.org/10.1155/2013/176213
26. Miller, P. S., Aricescu, A. R. (2014). Crystal structure of a human GABAA receptor. Nature, 512 (7514), 270–275. doi: http://doi.org/10.1038/nature13293
27. Storici, P., Capitani, G., Baise, D. D., Moser, M., John, R. A., Jansonius, J. N., Schirmer, T. (1999). Crystal structure of GABA aminotransferase, a target for antiepileptic drug therapy. Biochemistry, 38 (27), 8628–8634. doi: http://doi.org/10.1021/bi990478j
28. Löscher, W. (2017). Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs. Neurochemical research, 42 (7), 1873–1888. doi: http://doi.org/10.1007/s11064-017-2222-z

Received date 16.03.2020
Accepted date 10.04.2020
Published date 30.04.2020

Hanna Severina, PhD, Associate Professor, Department of Pharmaceutical Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: severina.ai@ukr.net

Natalya Voloshchuk, MD, Professor, Head of Department, Department of Pharmacology, National Pirogov Memorial Medical University, Pirogova str., 56, Vinnitsa, Ukraine, 21018
E-mail: voloshchuknatali@gmail.com

Narzullo Saidov, Doctor of Pharmaceutical Sciences, Professor, Department of Pharmaceutical Chemistry, Tajik National University, Rudaki str., 17, Dushanbe, Tajikistan, 734025
E-mail: narzullos@mail.ru

Victoriya Georgiyants, Doctor of Pharmaceutical Sciences, Professor, Head of Department, Department of Pharmaceutical Chemistry, National University of Pharmacy, Pushkinska str., 53, Kharkiv, Ukraine, 61002
E-mail: vgeor@ukr.net